ATE449858T1 - Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen - Google Patents

Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen

Info

Publication number
ATE449858T1
ATE449858T1 AT99402492T AT99402492T ATE449858T1 AT E449858 T1 ATE449858 T1 AT E449858T1 AT 99402492 T AT99402492 T AT 99402492T AT 99402492 T AT99402492 T AT 99402492T AT E449858 T1 ATE449858 T1 AT E449858T1
Authority
AT
Austria
Prior art keywords
retroviral
response
vector
production
cis
Prior art date
Application number
AT99402492T
Other languages
English (en)
Inventor
Pierre Charneau
Hueseyin Firat
Veronique Zennou
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE449858T1 publication Critical patent/ATE449858T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99402492T 1999-10-11 1999-10-11 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen ATE449858T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99402492A EP1092779B1 (de) 1999-10-11 1999-10-11 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE449858T1 true ATE449858T1 (de) 2009-12-15

Family

ID=8242139

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99402492T ATE449858T1 (de) 1999-10-11 1999-10-11 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
AT00972845T ATE326541T1 (de) 1999-10-11 2000-10-10 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
AT06001198T ATE441721T1 (de) 1999-10-11 2000-10-10 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT00972845T ATE326541T1 (de) 1999-10-11 2000-10-10 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
AT06001198T ATE441721T1 (de) 1999-10-11 2000-10-10 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen

Country Status (15)

Country Link
US (3) US7968332B2 (de)
EP (4) EP2169073B1 (de)
JP (2) JP4663943B2 (de)
CN (2) CN1840204B (de)
AT (3) ATE449858T1 (de)
AU (3) AU785060B2 (de)
CA (1) CA2387182C (de)
CY (4) CY1105149T1 (de)
DE (3) DE69941703D1 (de)
DK (4) DK2169073T3 (de)
ES (4) ES2447115T3 (de)
HK (1) HK1049861B (de)
IL (2) IL148901A0 (de)
PT (4) PT1092779E (de)
WO (1) WO2001027300A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
DK2169073T3 (da) 1999-10-11 2014-02-10 Pasteur Institut Vektor til fremstilling af immunterapeutiske præparater
PT1792997E (pt) 1999-10-12 2012-02-02 Pasteur Institut Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (de) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor-produktionssystemen
KR20040054699A (ko) 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP1712241A1 (de) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Intratumoral applizierbare Zusammensetzung zur Krebsbehandlung
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1739092A1 (de) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidische Antagonisten von Klasse III Semaphorin/Neuropilin Komplexen
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
ATE540689T1 (de) 2005-11-14 2012-01-15 Centre Nat Rech Scient Macroh2a non-histone domäne als hemmer der parp-1-aktivität und verwendung davon
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
WO2009019612A2 (en) * 2007-08-03 2009-02-12 Institut Pasteur Lentiviral gene transfer vectors and their medicinal applications
DK2385107T3 (en) 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
EP3202897B1 (de) 2010-12-09 2020-04-15 Institut Pasteur Diagnostische verwendung eines fusionspolypeptids, das ein virales protein und ein mgmt-enzym enthält
NO2788478T3 (de) 2011-12-09 2018-01-20
WO2014016383A2 (en) 2012-07-25 2014-01-30 Theravectys Glycoproteins for pseudotyping lentivectors
WO2015063706A1 (en) 2013-10-31 2015-05-07 Theravectys Lentiviral vectors for expression of hiv-1 antigens
EP3009144A1 (de) 2014-10-15 2016-04-20 Theravectys Lentivirale Vektoren zur Induzierung von CD4+- und+CD8+-Immunreaktionen bei der Impfung von Menschen
WO2015097650A1 (en) 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
JP6612237B2 (ja) 2014-01-27 2019-11-27 テラベクティ ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2016012623A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
EP3276006A1 (de) 2016-07-27 2018-01-31 Theravectys Lentivirale vektoren zur expression von hepatitis-b-virus (hbv)-antigenen
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
WO2019009979A1 (en) 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CSH-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR DISEASE THERAPY
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
CN108118070A (zh) * 2018-01-15 2018-06-05 南京驯鹿医疗技术有限公司 一种慢病毒制备方法
CN108588028B (zh) * 2018-04-26 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种靶向cdkn2a的cic细胞模型及其制备方法
WO2019210301A1 (en) 2018-04-27 2019-10-31 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
US20250044282A1 (en) 2019-05-10 2025-02-06 Institut Pasteur Live imaging system to visualize the retro-transcribed viral dna genome
CN115968377A (zh) 2020-05-20 2023-04-14 居里研究所 单域抗体及其在癌症治疗中的用途
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
JP2023535163A (ja) 2020-07-15 2023-08-16 アンスティテュ・パストゥール Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法
WO2022167831A1 (en) 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20240053339A1 (en) 2020-09-21 2024-02-15 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
US20240317890A1 (en) 2021-01-14 2024-09-26 Institut Curie Her2 single domain antibodies variants and cars thereof
BR112023018329A2 (pt) 2021-03-12 2023-10-10 Pasteur Institut Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral
EP4433081A1 (de) 2021-11-15 2024-09-25 Theravectys Lentivirale vektoren zur expression von antigenen des humanen papillomavirus (hpv) und deren implementierung bei der behandlung von hpv-induzierten krebsarten
CN119894530A (zh) 2022-07-27 2025-04-25 瑟拉维克提斯公司 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发的癌症中的应用
EP4604993A2 (de) 2022-10-21 2025-08-27 Institut Pasteur Nichtstrukturelle flavivirus-antigene exprimierende polynukleotide und lentivirale vektoren aus der gruppe von denv, zikv und yfv, die schützende cd8+-t-zellimmunität in einem wirt induzieren
EP4624494A1 (de) 2024-03-29 2025-10-01 Institut Curie Her2-einzeldomänenantikörper und verwendungen davon

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684094A5 (de) * 1988-03-21 1994-07-15 Viagene Inc Rekombinante Retroviren.
GB9213559D0 (en) * 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
EP0611822B1 (de) 1993-02-17 2002-05-22 Wisconsin Alumni Research Foundation Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2247091A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
EP0991771A2 (de) * 1997-03-06 2000-04-12 Klaus Überla Vektoren, die auf lentiviren basieren und vektorsysteme
WO1998046083A1 (en) 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
PT1447414E (pt) * 1997-10-10 2007-07-18 Us Gov Health & Human Serv Péptidos antagonistas do antigénio carcinoembrionário ( cea ).
EP1032420A4 (de) * 1997-11-14 2004-09-15 Euro Celtique Sa Immunoglobulin moleküle mit synthetischer variabler region und modifizierter spezifität
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US6555342B1 (en) * 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
DK2169073T3 (da) 1999-10-11 2014-02-10 Pasteur Institut Vektor til fremstilling af immunterapeutiske præparater
PT1792997E (pt) 1999-10-12 2012-02-02 Pasteur Institut Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
ES2332930T3 (es) 2010-02-15
AU2010203111A1 (en) 2010-08-12
US8349606B2 (en) 2013-01-08
EP1092779A1 (de) 2001-04-18
ATE326541T1 (de) 2006-06-15
US8652807B2 (en) 2014-02-18
PT1222300E (pt) 2006-09-29
CY1114819T1 (el) 2016-12-14
IL148901A0 (en) 2002-09-12
CA2387182C (en) 2010-12-21
ES2337429T3 (es) 2010-04-23
CA2387182A1 (en) 2001-04-19
CN1379820A (zh) 2002-11-13
WO2001027300A1 (en) 2001-04-19
AU1143501A (en) 2001-04-23
DK2169073T3 (da) 2014-02-10
DE60028066D1 (de) 2006-06-22
CN1379820B (zh) 2011-04-13
JP4663943B2 (ja) 2011-04-06
EP1222300A1 (de) 2002-07-17
AU2006252062B2 (en) 2010-04-22
EP2169073A1 (de) 2010-03-31
HK1093523A1 (en) 2007-03-02
DK1650309T3 (da) 2009-11-30
ATE441721T1 (de) 2009-09-15
HK1049861B (en) 2006-12-22
DE60028066T2 (de) 2007-01-18
AU2010203111B2 (en) 2012-01-19
DK1222300T3 (da) 2006-09-18
US7968332B2 (en) 2011-06-28
CY1110551T1 (el) 2015-04-29
EP1650309A1 (de) 2006-04-26
CN1840204B (zh) 2011-09-07
PT1650309E (pt) 2009-11-18
CN1840204A (zh) 2006-10-04
CY1110611T1 (el) 2015-04-29
EP2169073B1 (de) 2013-11-13
EP1650309B1 (de) 2009-09-02
AU785060B2 (en) 2006-09-14
US20040081636A1 (en) 2004-04-29
EP1222300B1 (de) 2006-05-17
ES2447115T3 (es) 2014-03-11
JP2003511080A (ja) 2003-03-25
JP5265643B2 (ja) 2013-08-14
DE69941703D1 (de) 2010-01-07
DK1092779T3 (da) 2010-02-15
PT1092779E (pt) 2010-01-19
IL204703A0 (en) 2010-11-30
US20110250650A1 (en) 2011-10-13
HK1049861A1 (en) 2003-05-30
PT2169073E (pt) 2014-02-20
ES2262545T3 (es) 2006-12-01
US20130157357A1 (en) 2013-06-20
AU2006252062A1 (en) 2007-01-18
JP2011078420A (ja) 2011-04-21
EP1092779B1 (de) 2009-11-25
DE60042903D1 (de) 2009-10-15
CY1105149T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
ATE449858T1 (de) Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
NZ222210A (en) Hair care products containing dimethyl diallyl ammonium chloride/acrylic acid-type copolymers
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
JP2018513681A5 (de)
DK1809743T3 (da) Strukturel nukleinsyre-styret kemisk syntese
DE69934596D1 (de) Transkriptionsaktivator prtt aus dem pilz aspergillus niger verwendbar in verfahren zur herstellung von polypeptiden
WO2003074073A3 (fr) Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications.
EP1409694A4 (de) Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
PT630409E (pt) Vectores nao oncovirais deficientes no empacotamento baseados no mpmv
SE8702272D0 (sv) A fibrnectin binding protein as well as its preparation
WO2002092822A3 (en) Leaf specific gene promoter of coffee
DE69618574D1 (de) Vom desmingen abstammende amplifizierungssequenzen, vektoren, die diese enthalten und anwendungen derselben zur herstellung von proteinen
DE50213036D1 (de) Verfahren zur isomerisierung von allylalkoholen
WO1999003981A8 (en) Nucleic acid expression constructs incorporating a heterologous intron whose natural position is within the 5'untranslated region of its gene
WO1999002724A3 (en) Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods
AP2002002509A0 (en) Recombinant oleosins from cacao and their use as flavoring or emulsifying agents.
SE9503379D0 (sv) A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
ATE226256T1 (de) Antifungale proteine, dafür kodierende dna, und diese enthaltende wirtzelle
Hecht Virtual slavery.
Henry Shock treatment.
De Gaspari Six ways to make your plants safer.
ES2008391A6 (es) Un metodo para producir isopenicilina n sintetasa.
IT8619987A0 (it) Tingibordi orizzontale per prodotti di pelletteria, come cinture esimili.
WO2001027297A3 (en) VERSATILE rpL34 PROMOTER ELEMENTS AND USE THEREOF
Church et al. Fractured hopes.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1092779

Country of ref document: EP